Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Zhe Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0389-4671; OpenAlex author ID A5101880415. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 5 papers · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 26

  1. Integrated scRNA-Seq and functional profiling reveal CD52 as a driver of pancreatic ductal adenocarcinoma metastasis and immunosuppression. Co-author DOI 10.1038/s41389-026-00637-x↗
  2. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Co-author DOI 10.1038/s41392-026-02741-1↗
  3. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3. Co-author DOI 10.1016/j.isci.2024.109406↗
  4. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  5. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune mic… Co-author DOI 10.1016/j.canlet.2022.216020↗
  6. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. Co-author DOI 10.1093/bjs/znac375↗
  7. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  8. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  9. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. Co-author DOI 10.1186/s13046-020-01787-5↗
  10. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  11. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  12. Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progressi… First author DOI 10.1155/2020/2340124↗
  13. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. Co-author DOI 10.1158/1541-7786.mcr-19-0718↗
  14. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Co-author DOI 10.1186/s12935-020-1147-9↗
  15. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy]. Last author DOI 10.3760/cma.j.cn112139-20200422-00323↗
  16. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Co-author DOI 10.1002/cam4.2384↗
  17. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. Co-author DOI 10.1186/s12943-019-1103-2↗
  18. NF-κB in pancreatic cancer: Its key role in chemoresistance. Co-author DOI 10.1016/j.canlet.2018.02.011↗
  19. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Co-author DOI 10.1186/s12943-017-0755-z↗
  20. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s13046-018-0947-4↗
  21. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.08.006↗
  22. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. Co-author DOI 10.1186/s13046-016-0406-z↗
  23. Localized Autoimmune Pancreatitis: Report of a Case Clinically Mimicking Pancreatic Cancer and a Literature Review. Co-author DOI 10.1097/md.0000000000001656↗
  24. MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP. Co-author DOI 10.1371/journal.pone.0116934↗
  25. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Co-author DOI 10.18632/oncotarget.1890↗
  26. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Co-author DOI 10.18632/oncotarget.2184↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 25 shared papers, 2014–2026 · strength 2.88
  2. Lei You · 19 shared papers, 2014–2024 · strength 1.81
  3. Gang Yang · 15 shared papers, 2017–2024 · strength 1.63
  4. Yueze Liu · 12 shared papers, 2019–2024 · strength 1.52
  5. Yupei Zhao · 15 shared papers, 2014–2026 · strength 1.40
  6. Jiangdong Qiu · 10 shared papers, 2018–2026 · strength 1.27
  7. Wenhao Luo · 8 shared papers, 2019–2026 · strength 1.14
  8. Mengyu Feng · 10 shared papers, 2017–2023 · strength 0.99
  9. Fangyu Zhao · 9 shared papers, 2019–2023 · strength 0.98
  10. Jiangdong Qiu · 7 shared papers, 2019–2024 · strength 0.90
  11. Jinxin Tao · 4 shared papers, 2023–2026 · strength 0.76
  12. Hua Huang · 7 shared papers, 2014–2024 · strength 0.75
  13. Guangbing Xiong · 6 shared papers, 2016–2023 · strength 0.57
  14. Guangyu Chen · 4 shared papers, 2020–2023 · strength 0.50
  15. Jianchun Xiao · 4 shared papers, 2020–2024 · strength 0.49
  16. Yifan Fu · 2 shared papers, 2024–2026 · strength 0.41
  17. Hao Chen · 2 shared papers, 2020–2026 · strength 0.36
  18. Yuejuan Cheng · 1 shared paper, 2026 · strength 0.26
  19. Chunmei Bai · 1 shared paper, 2026 · strength 0.26
  20. Yuanyang Wang · 1 shared paper, 2026 · strength 0.25
  21. Zeyu Zhang · 1 shared paper, 2026 · strength 0.25
  22. Ruobing Wang · 1 shared paper, 2024 · strength 0.20
  23. Dan Su · 1 shared paper, 2024 · strength 0.20
  24. T P Zhang · 1 shared paper, 2020 · strength 0.19
  25. Jinshou Yang · 2 shared papers, 2019–2020 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.